Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking

Yuyan Jin, Bruce G. Pollock, Kim Coley, Del Miller, Stephen R. Marder, Jeff Florian, Lon Schneider, Jeffrey Lieberman, Margaret Kirshner, Robert R. Bies

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8 to 32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One- and 2-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness-of-fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A 1-compartment linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18 200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48% higher in nonsmoking African Americans than in nonsmoking other races (512 L/h vs 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalJournal of clinical pharmacology
Volume50
Issue number1
DOIs
StatePublished - Jan 1 2010

Keywords

  • Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE)
  • Perphenazine
  • Population pharmacokinetics
  • Race and smoke
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking'. Together they form a unique fingerprint.

  • Cite this

    Jin, Y., Pollock, B. G., Coley, K., Miller, D., Marder, S. R., Florian, J., Schneider, L., Lieberman, J., Kirshner, M., & Bies, R. R. (2010). Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking. Journal of clinical pharmacology, 50(1), 73-80. https://doi.org/10.1177/0091270009343694